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Abstract: 
Administration of ghrelin, an endogenous ligand for the growth hormone secretagogue 
receptor 1a (GHSR 1a), induces potent stimulating effects on GH secretion and food intake. 
However, more than seven years after its discovery, the role of endogenous ghrelin remains 
elusive. Recently a second peptide, obestatin, also generated from proteolytic cleavage of 
preproghrelin has been identified. This peptide inhibits food intake and gastrointestinal 
motility but does not modify in vitro GH release from pituitary cells. In this study we have 
reinvestigated obestatin functions by measuring plasma ghrelin and obestatin levels in a 
period of spontaneous feeding in ad libitum fed and 24h-fasted mice. While fasting resulted in 
elevated ghrelin levels, obestatin levels were significantly reduced. Exogenous obestatin per 
se did not modify food intake in fasted and fed mice. However, it inhibited ghrelin orexigenic 
effect that were evident in fed mice only. The effects of obestatin on GH secretion were 
monitored in superfused pituitary explants and in freely moving rats. Obestatin was only 
effective in vivo to inhibit ghrelin stimulation of GH levels. Finally, the relationship between 
octanoylated ghrelin, obestatin and GH secretions was evaluated by iterative blood sampling 
every 20 minutes during 6 hours in freely moving adult male rats. The half-life of exogenous 
obestatin (10 µg iv) in plasma was about 22 minutes. Plasma obestatin levels exhibited an 
ultradian pulsatility with a frequency slightly lower than octanoylated ghrelin and GH. 
Ghrelin and obestatin levels were not strictly correlated. 
  In conclusion these results show that obestatin, like ghrelin, is secreted in a pulsatile 
manner and that in some conditions; obestatin can modulate exogenous ghrelin action. It 
remains to be determined whether obestatin modulates endogenous ghrelin actions. 
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Introduction: 
Ghrelin was identified in 1999 as the endogenous ligand for the growth hormone 
secretagogue receptor 1a (GHSR 1a) (1). Soon after its discovery, in addition to its strong GH 
releasing activity (2, 3), ghrelin was found to increase food intake, downregulate energy 
expenditure and conserve body fat, causing weight gain and adipogenesis (4-7). However, if 
exogenous ghrelin actions are well established, the role of endogenous ghrelin is still unclear. 
Ghrelin antagonists have significant effects on these two functions (8-10) and active 
vaccination against ghrelin immunoconjugates decreases feed efficiency, relative adiposity 
and body weight gain in mature rats (11). Mice invalidated for the preproghrelin or ghrelin 
receptor gene do not display a major phenotype in term of body growth (12, 13) but are 
protected against early-onset obesity (14, 15). The recent identification of obestatin, a new 
peptide derived from preproghrelin which has been reported to bind to and activates the 
orphan receptor GPR39 (16, 17) may explain such discrepancies. Indeed, obestatin exhibits 
opposite effects of ghrelin on energy homeostasis and gastrointestinal function but appears 
ineffective on GH secretion (17).  
In the present work we further investigated obestatin’s ability to modulate spontaneous 
or ghrelin induced food intake and GH secretion. Plasma obestatin, ghrelin and GH levels 
were monitored by selective assays. Food intake was measured at the onset of the dark phase 
in fed and in 24h-fasted/refed mice. GH secretion was evaluated ex vivo from superfused rat 
pituitaries and in vivo in freely moving male rats.  Finally, the relationship between obestatin, 
(18-20) ghrelin and GH secretion was assessed by sampling blood every 20 min for 6 
consecutive hours, the first three corresponding to the end of the light-on period and the last 
three to the beginning of the light-off period. 
Materials and Methods 
Animals: 
Four weeks before experiments, adult male C57Bl/6 mice and Sprague-Dawley rats (Charles 
River Laboratories, Inc., L’Arbresle, France) weighing respectively between 20 and 25g and 
100 and 125 g at the onset of the experiment were housed individually in transparent plastic 
containers placed in a sound proof room with controlled temperature (22–24 C) and 
illumination (12 h light, 12 h dark schedule with lights off at 1700 h). They had free access to 
food and water and they were regularly weighed and handled in order to minimize 
manipulation stress. Animal experiments were performed according to the guidelines of the 
French Act of Animal Care and Experimentation (1990; registration number 75–343). All 
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efforts were made to minimize pain and suffering and to reduce the number of animals used. 
In vivo experiments 
Mouse experiments. For the food intake experiments, C57Bl/6 mice had free access
to food and water until the fasting period. Every other day during the two weeks before the 
experiments, mice received intra-peritoneal saline injections in order to minimize stress. They 
were assigned randomly to the fast and fed groups. One day before the experiment a group 
was fasted for 24h. On the day of the experiment, animals received an intra-peritoneal (ip) 
injection of saline, ghrelin, obestatin or obestatin + ghrelin (1µmol/kg each; NeoMPS 
Strasbourg, France) one hour before the onset of the dark period. Fasted animals were given 
access to food just after the injection. In a first set of experiments, blood samples were 
withdrawn from the jugular vein at 1600h after anaesthesia with ketamine-xylazine in order to 
determine endogenous levels of ghrelin, obestatin, and glucose at injection time. In a second 
one, food intake was monitored 1, 3, 5 and 18h after the injection. Finally, in a third one, 
animals were decapitated one hour after peptide injection and blood was sampled in order to 
determine glucose levels (measured by glucose oxydase; Beckman analyzer II; Beckman 
Coulter, Fullerton, CA).  
Rat experiments. Two days before blood sampling, an indwelling cannula was 
inserted into the right atrium as previously described (21). Two hours before the sampling 
period, the distal extremity of the cannula was connected to a polyethylene catheter filled with 
25 IU/ml heparinized saline. Blood samples were collected on EDTA (1mg/ml) and p-
hydroxy-mercuribenzoic acid (PHMB, Sigma, Saint Quentin Fallavier, France) (0.36mg/ml) 
to avoid ghrelin degradation, immediately centrifuged and plasma was stored at -20°C until 
hormone assays. Blood from donor rats was regularly reinjected to attenuate hemodynamic 
modifications. 
In experiment 2, saline, obestatin (10µg/rat), ghrelin (10µg/rat) or obestatin plus 
ghrelin were administered intravenously at 1000h and blood samples withdrawn just before 
and 5, 10, 20, 30, 45 and 60 min after injection for GH determination. 
 In experiment 3, the half life of obestatin in plasma was determined. Blood samples 
were collected 0, 5, 10, 20, 30, 45 and 60 minutes after IV injection of 10 µg of obestatin and 
plasma obestatin levels were measured.  Half life was calculated as t ½=ln(2)/Kel where 
Kel=-slope. 
In experiment 4, blood was sampled every 20 min from 1400h to 2000h,  in order to 
compare endogenous obestatine, octanoylated ghrelin and GH secretory parameters. 
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Ex vivo experiments 
Rats were sacrificed by decapitation. Pituitaries were rapidly dissected, washed for 30 
min in oxygenated Dulbecco’s modified Eagle’s medium (with L-glutamine, 4.5 g glucose, L-
1 and 25 mM HEPES) containing 0.1% bovine serum albumin, placed in perifusion chambers 
(vol 0.3 ml) and superfused at a rate of 0.1 ml/min with the same medium. After a 120-min 
equilibration period, effluents were collected every 5 min. Peptides were added to the medium 
during 15-min periods. Samples were frozen until GH determinations.  
Hormone assays: 
Octanoylated ghrelin was measured by an in-house immuno-enzymatic assay using  
polyclonal rabbit antibodies made against N-terminal rat ghrelin (kindly provided by Dr. 
Hosoda, Osaka, Japan), and human ghrelin coupled to acetylcholinesterase (Spibio, Saclay, 
France) as tracer. The sensitivity was 6 pmole/L and the intraassay coefficient of variation 
was 7 %.  
Obestatin levels were determined with a commercial RIA kit (Phoenix, Belmont, CA). 
We have verified that rat pre-proghrelin 52-85 and 86-117 (Phoenix, Belmont, CA) do not 
cross-react up to the concentration of 3973 pmole/L. The sensitivity of this assay was 4 
pmole/L and the intraassay coefficient of variation was  8  %. 
Plasma GH concentrations were evaluated by EIA as previously  described (22). 
Values are reported in terms of rGH-RP2, with sensitivity of 0.6 ng/ml and intra- and 
interassay coefficients of variation were 4 and 14 % respectively 
Statistical analysis: 
Acylated ghrelin, obestatin and GH pulse analysis was performed using the Cluster 8 
software (23)  with the t value set to 2 to maintain false positive rates under 1%. Number of 
point for a peak and number of point for a nadir were set to 1 and 2 respectively.  
Approximative entropy was calculated using the MC-ApEn software using R-value set 
to 0.2 and number of MC cycle set to 1000.  
These programs are avaible from: http://mljohnson.pharm.virginia.edu/home.html.
 Values are given as means ± sem, and statistical analysis was performed by ANOVA 
and paired t test using the JMP IN 5.1 software (SAS Institute Inc., Cary, NC). 
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Results: 
24 hours of fasting significantly reduced glycaemia (131±18 vs 313±44 mg/dl in ad 
libitum fed mice; P<0.01) and obestatin levels (256±6 vs 320±12 pmole/L; P<0.01) while it 
increased octanoylated ghrelin (787±225 vs 279±105 pmole/L; P= 0.087) (n=4). 
Obestatin effects on spontaneous and ghrelin induced food intake at the onset of the 
dark period, in fed and 24h fasted mice. 
As shown on figure 1, during the light-off period, spontaneous cumulative food 
consumption (after 1,3, 5 and 18h) was lower in ad libitum fed than in fasted mice given 
access to food. Administration of obestatin (1 µmol/kg body weight ip) one hour before light-
off was ineffective to modify food intake in fed (fig 1B, 1C) or fasted/refed (fig 1A, 1C) mice 
during the following 18 hours. In the same conditions ghrelin (1 µmol/kg body weight ip) 
significantly stimulated food intake in fed mice only and co-administration of obestatin 
inhibited this effect. In fasted/refed mice, cumulative food intake was similar to that of 
ghrelin- treated fed mice. 
In fed and fasted animals, ghrelin increased plasma glucose levels, one hour after the 
injection (Fed: saline 177.0±6.6 mg/dl, ghrelin: 221.4±18.0 mg/dl; P<0.05 vs saline; Fasted: 
saline: 249.6±26.7 mg/dl, ghrelin: 342.4±24.8 mg/dl; P<0.01 vs saline). Obestatin did not 
affect basal (Fed: 204.6±8.9 mg/dl; Fasted: 240.0±26.0 mg/dl) or ghrelin-induced glucose 
levels (Fed: 222.2±10.3 mg/dl; Fasted: 321.6±27.5 mg/dl). 
Ex vivo and in vivo effects of obestatin on spontaneous and ghrelin induced GH release 
As shown on figure 2A, ghrelin (10-7M) rapidly stimulated GH release from 
superfused pituitaries ex vivo. Obestatin (10-7 and 10-6 M) did not affect spontaneous or 
ghrelin-induced GH release. 
In vivo, intravenous administration of rat/mouse ghrelin (10µg/rat) increased plasma 
GH levels as early as 5 min after the injection. The effect was maximal at 10 min and returned 
to basal levels after 45 to 60 minutes. Under the same conditions, obestatin (10µg/rat) did not 
change basal GH levels but markedly inhibited ghrelin-induced GH secretion (Figure 2B). 
Obestatin, ghrelin and GH levels in freely moving rats. 
Determination of plasma obestatin concentrations from 5 to 60 min after synthetic 
obestatin administration (10 µg, iv) in freely moving rats showed that the peptide half life in 
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plasma was 22±2 minutes (n=6) (Figure 3). This permitted to use a 20 min sampling 
periodicity during 6 hours to compare obestatin and ghrelin secretory profiles. 
Individual profiles of obestatin, ghrelin and GH secretion are displayed on figure 4. 
Plasma obestatin levels exhibited pulsatile variations of moderate amplitude, comparable with 
those of ghrelin. 
Pulsatility parameters for obestatin, ghrelin and GH secretory profiles are indicated in 
table 1.  Peak amplitudes are similar for ghrelin and obestatin (increase of 54% for obestatin 
and 81% for ghrelin) and of lesser amplitude than those of GH (increase of 370%). Obestatin 
pulse frequency is slightly lower than that of octanoylated ghrelin or GH. Regularity of 
secretion determined by approximative entropy (ApEn) is very similar for obestatin, ghrelin, 
and GH. 
When all samples were pooled, obestatin and ghrelin levels were significantly but 
weakly correlated (r2=0.0297, P=0.0344). When data from each rat were treated separately, 
significant correlations between ghrelin and obestatin were only observed in 3 out of 8 rats 
(individual r2=0.3147; 0.3990; 0.3566, with  P=0.0125, 0.0049, 0.0069 respectively; all others 
r2<0.05; overall correlation for these 3 rats, r2=0.1272, P=0.007).  
Discussion: 
In the present study we observe that, in some conditions, obestatin can inhibit ghrelin 
effects on food intake, depending on the feeding status, and on GH secretion. However, it is 
ineffective per se on these parameters. 
Our results on food intake are slightly different from those originally reported by  
Zhang et al. who observed an inhibitory effect of obestatin on spontaneous food intake in 
refed mice (17). In their study, obestatin effects were only observed in refed animals, 
sacrificed 2 hours after light onset whether our data were obtained just after the onset of the 
light-off period when animals begin to eat spontaneously (24). More recently, the vast 
majority of studies (18, 20, 25-29) with one exception (30), reported no effect of obestatin per 
se or on ghrelin- induced food intake in rats and mice (fed or fasted/refed), whatever the route 
of administration and mode of obestatin dilution. Effects of orexigenic/anorexigenic peptides 
such as ghrelin and obestatin likely depends upon the relative concentrations of other 
orexigenic/anorexigenic factors at the time of injection. Indeed, we observed that, injected one 
hour before light off, ghrelin stimulates food intake in fed animals but is ineffective at the 
same dose in fasted ones given access to food. Similar results were reported when 
experiments were performed during the light-on period with a very low increase of food 
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intake in refed animals compared with that of ad libitum ones (30% vs 320%) (17, 31). 
Endogenous ghrelin concentrations are markedly increased during fasting (125% after 24h 
fasting) in mice (32) and to a lesser extent just before light off (20 to 30%) in rats (33) (and 
Zizzari et al, unpublished data). The fact that ghrelin is effective only in fed mice and that in 
refed mice cumulative food intake is of the same magnitude than in ghrelin treated fed ones 
suggests that, beyond a certain threshold, additional exogenous ghrelin cannot further increase 
an already elevated food consumption. Reciprocally, the inefficiency of obestatin to alter 
spontaneous food intake at the beginning of the light-off period is probably not due to plasma 
ghrelin level increases since obestatin is able to counteract the effect of very high doses of 
exogenous ghrelin (1 µmol/kg). Other orexigenic/anorexigenic factors exhibit circadian 
variations which could modify obestatin or ghrelin responses. Numerous studies show 
modifications of NPY, GAL, β-endorphin and POMC gene expression at the onset of the dark 
phase (34-36) and it will be of interest to test obestatin and ghrelin responses in presence of 
variable concentrations of these factors. 
It is generally believed that ghrelin exerts its orexigenic effect mainly by activating 
GHSR1a on hypothalamic arcuate nucleus NPY/AgRP neurons (37-40) but the mechanisms 
by which obestatin could modulate food intake are not yet known. Obestatin exerts its 
anorectic effect after intracerebroventricular administration at a low dose (8nmol/kg) 
suggesting a central action (17). Obestatin was originally reported to bind to GPR39, an 
orphan receptor, which shares similarities with GHSR1a (16, 17). GPR39 mRNA has been 
detected by reverse transcriptase polymerase chain reaction in the hypothalamus and 125I 
obestatin binding sites were reported in the same region (16, 17). Nevertheless, recent studies 
failed to confirm the presence of specific radio-labelled obestatin binding on GPR39 or 
activation of this receptor by obestatin (18-20). In preliminary experiments, we also observed 
that obestatin did not modify several signal transduction pathways in GPR-39 transfected cells 
(Pantel, et al unpublished data). It remains to determine which is the receptor for obestatin and 
how obestatin interferes with GHSR 1a to inhibit ghrelin stimulated food consumption. Since 
obestatin inhibits jejunal contractile activity and suppress gastric empting activity  (17),  it 
cannot be excluded that its anorectic effect relies mostly on peripheral sites of action. The 
inhibition of jejunal contraction could generate an afferent vagus signal to induce satiety in 
the CNS. 
As already reported (17, 27), we did not observe any effect of obestatin on 
spontaneous or ghrelin-induced GH release ex vivo .  In contrast, when administered iv to rats, 
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obestatin significantly inhibited ghrelin stimulation of GH secretion. Ghrelin increases plasma 
GH levels  by acting directly on pituitary but also indirectly at the hypothalamic level where it 
stimulates GHRH secretion (41) and decreases somatostatin release (3). Alternately, gastric 
vagal afferents are also an important pathway conveying ghrelin signals for GH secretion to 
the brain (42) .  
The present study shows, for the first time, that obestatin secretion is pulsatile and 
displays an ultradian rhythmicity, very similar to ghrelin and GH secretion. Interestingly 
however, plasma ghrelin and obestatin levels are not strictly correlated and the number of 
obestatin pulsatile episodes may seem slightly lower than the one observed for ghrelin and 
GH secretion. As obestatin and ghrelin are derived from the same gene, this lack of strict 
correlation supports the notion that obestatin is a physiologically relevant peptide and not only 
a non-functional connective peptide. Such an hypothesis is further substantiated by the 
differential effect of fasting on ghrelin and obestatin levels, ghrelin being markedly increased 
and obestatin slightly decreased after 24 hours of fasting. This strongly suggests that the 
secretion of the two peptides is regulated by the nutritional status in an opposite manner. It 
was previously shown that proopiomelanocortin, another multipeptide precursor, is cleaved 
into several bioactive fragments that include the anorectic α and β melanocyte-stimulating 
hormones and the orexigenic β-endorphin and that tissue-specific enzymes determine which 
of those peptides are generated (43). It remains to be determined whether a differential tissue 
specific post-translational process exists in the case of proghrelin and obestatin processing. 
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Figure Legends:
Table 1: Analysis of octanoylated ghrelin, obestatin and GH pulsatility parameters.  
Data are mean±sem of 8 rats. 
Figure 1: Obestatin effects on spontaneous and ghrelin-induced food intake, in fed and 24h 
fasted mice, during the dark period.
Cumulative food intake 1, 3, 5 hours after injection of saline (blue square), 1µmol/kg ghrelin 
(green square), 1µmol/kg obestatin (dark triangle) or 1µmol/kg obestatin + ghrelin (red 
triangle) : Panel A :  in 24 h refeeding fasted mice (n= 20, 5 in each group) ; Panel B : in ad 
libitum fed mice (n= 20, 5 in each group) 
a: ghrelin vs saline, P<0.01 ; b : ghrelin vs obestatin, P<0.01 ; c : ghrelin vs obestatin + 
ghrelin, P<0.05 ; d : ghrelin vs obestatin, P<0.05 
Panel C : Cumulative food intake 18 h post injection in 24 h fasted (left) and ad libitum fed 
(right) mice receiving saline (blue), 1µmol/kg ghrelin (green), 1µmol/kg obestatin (dark) or 
1µmol/kg obestatin + ghrelin (red) 
a : ghrelin vs saline, P<0.05 ; b : ghrelin vs obestatin, P=0.06 
Figure 2:  Obestatin effects on spontaneous or ghrelin induced GH secretion in the rat 
 Panel A : Mean profile of GH release from superfused rat pituitaries in basal condition and 
after infusion of obestatin 10-6M (dark triangle), ghrelin 10-7M (green square), obestatin 10-
7M + ghrelin 10-7M (pink triangle), obestatin 10-6M + ghrelin 10-7M (red triangle). The 
different peptides were infused during 15 minutes (materialised by dotted line). Each point 
and vertical bar indicates mean +/- sem of 4 chambers. 
Panel B : Effect of 10 µg obestatin (dark triangle), 10 µg ghrelin (green square) or 10 µg 
obestatin + ghrelin (red triangle) on GH secretion in freely moving rats. The peptides were 
injected at t=0, and blood were collected pre-injection and 5, 10, 20, 30, 45, 60 minutes post 
injection. Data are means +/- sem. Number of animals are indicated in parentheses.  
*: Ghrelin vs Obestatin + Ghrelin, P<0.05; #: Ghrelin vs Obestatin, P<0.05  
Figure 3: Determination of exogenous obestatin half-life in rat plasma. 
Obestatin immunoreactivity was detected by RIA in rat plasma after iv injection of 10 µg 
synthetic peptide. Data are expressed as % obestatin concentrations measured immediately 
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after the injection. Values are the means±sem of six determinations. A semilogarithmic plot of 
the data is given in the inset. 
Figure 4 : Ghrelin, obestatin and GH profiles in freely moving rats 
Representative octanoylated ghrelin (triangle), obestatin (red square) and GH (diamond-
shaped) secretory patterns during a 6-h sampling period (3-h during the light period and 3-h 
during the dark period) in four freely moving male rats.  
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